slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 4,441-4,470
Pages 350
Rows per page 30
Slide type
4,441-4,470 of 10,471
30
The slide uses Manhattan plots to visualize genetic associations over time (2016, 2017, 2021) and a line chart to show the growth of independent hits from 2015 to 2020.23andMe | Investor Presentation Deck | 58 slides · 23andMe
Pitch deck Investor relations 1 hit
31
The slide uses a grid of small-multiple charts to demonstrate breadth, with a specific callout for NAFLD at the bottom.23andMe | Investor Presentation Deck | 58 slides · 23andMe
Pitch deck Investor relations 1 hit
42
The slide uses a scatter plot to demonstrate a positive correlation (rho = 0.86) between CD200R1 and CD45 in KIRC (Clear cell renal carcinoma) samples.23andMe | Investor Presentation Deck | 58 slides · 23andMe
Pitch deck Investor relations 1 hit
55
The slide uses a '+' notation to illustrate the integration of services.23andMe | Investor Presentation Deck | 58 slides · 23andMe
Pitch deck Investor relations 1 hit
14
The chart demonstrates dose-dependent efficacy of Epetraborole (EBO) against M. avium 2285 (R).AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
The charts demonstrate dose-dependent efficacy and synergy between EBO and SoC.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
Includes a timeline diagram of the study design and bulleted clinical outcomes.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
The slide highlights the therapeutic potential of the drug by showing superior accumulation at the site of infection.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
04
The slide uses a mix of qualitative achievements and quantitative hiring/headcount data to demonstrate organizational health.Apollo Global Management | Investor Presentation Deck | 37 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
30
The slide uses a combination of high-level investment metrics and a logo-grid to establish credibility and market presence.Apollo Global Management | Investor Presentation Deck | 37 slides · Apollo Global Management
Pitch deck Investor relations 1 hit
10
Includes waterfall plot for partial response and spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
11
The slide uses a process-flow diagram to map patient cohorts to clinical outcomes and subsequent study advancement decisions.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
12
Includes a spider plot for lesion change and a Kaplan-Meier survival curve.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
13
Includes Kaplan-Meier survival curve and waterfall plot for lesion change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
14
Clinical trial data showing PFS at 3 months for Liposarcoma and Synovial Sarcoma cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
15
Includes specific clinical trial terminology (CTCAE, SAE, RP2D, Q2W).BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
17
The chart is a waterfall plot showing maximum change from baseline for different patient cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Clinical trial data for BA3011 in NSCLC patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Clinical trial data presentation for oncology drug candidate.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
25
The chart displays longitudinal data for two specific patients, showing sustained complete response.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The slide uses a table to present clinical outcomes for specific tumor types, emphasizing the first-in-class potential of the therapy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
33
The chart shows tumor volume over time for three different antibody treatments, with the CAB-EpCAM x CAB-CD3 showing the best efficacy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
08
The slide uses a structured grid layout to categorize key performance indicators.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
09
The slide uses a list-based timeline/milestone format to highlight growth across five key areas.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
17
Includes product image and key performance metrics.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Slide highlights both historical traction (>3.6bn doses) and future growth vectors (label expansion, boosters, next-gen vaccines).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
04
Slide 4 of the Cazoo pitch deck.Cazoo | Investor Presentation Deck | 16 slides · Cazoo
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
05
The slide uses a 2x2 grid layout to present four key performance indicators with year-over-year or quarter-over-quarter growth comparisons.Cazoo | Investor Presentation Deck | 16 slides · Cazoo
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
09
The slide presents key performance indicators (KPIs) for Cazoo, showing significant year-over-year growth in both units sold and revenue.Cazoo | Investor Presentation Deck | 16 slides · Cazoo
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit